AADI - Aadi Bioscience, Inc.
3.02
0.005 0.166%
Share volume: 256,955
Last Updated: Tue 21 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.36%
PREVIOUS CLOSE
CHG
CHG%
$3.02
0.04
0.01%
Fundamental analysis
9%
Profitability
0%
Dept financing
23%
Liquidity
72%
Performance
0%
Performance
5 Days
1.34%
1 Month
5.59%
3 Months
45.19%
6 Months
100.00%
1 Year
79.76%
2 Year
-76.46%
Key data
Stock price
$3.02
DAY RANGE
$2.99 - $3.09
52 WEEK RANGE
$1.21 - $3.81
52 WEEK CHANGE
$76.61
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Recent news